MDx Company DxNA Buying PCR-based Assay Development Firm PathoGene | GenomeWeb
Home » MDx Company DxNA Buying PCR-based Assay Development Firm PathoGene

MDx Company DxNA Buying PCR-based Assay Development Firm PathoGene

Jul 17, 2013
|
a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics shop DxNA has signed a letter of intent to acquire PCR-based assay development company PathoGene, the companies said this week.

Terms of the deal were not revealed, but the companies said the acquisition is anticipated to be completed during the next six months, contingent on the completion of due diligence and other conditions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Articles

Nov 13, 2015

Scienion, Grenier Bio-One Collaborate on Rapid Multiplex Dx for Infectious Disease

Mar 09, 2016

InSilixa, DNA Software Partner on Infectious Disease Detection Panels

Dec 28, 2015

Outbreak Tracking, Infectious Disease Diagnostics Becoming Key Applications for NGS

Premium
May 05, 2016

MRSA Genomes Scrutinized for Clues to Routine Surveillance

Jul 06, 2016

Host Expression Signature Differentiates Bacterial, Viral Infections; May Lead to Dx Device

Premium
Mar 28, 2016

Great Basin Multiplex Staph ID/R Blood Culture Panel Gets FDA Clearance

The Scan

This Week in Science

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

Science in Coach

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Funny Side of Science

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

When the FDA Plays Hardball

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."

What's Popular?

In PCR

  1. Great Basin Secures $75M Funding Commitment in Senior Convertible Notes

  2. CDC Purchases $2.5M in Lab Supplies to Expand Zika Testing Capacity

  3. Axela, Thermal Gradient Ink Deal for Technology Integration

  4. Piper Jaffray Downgrades Hologic, Citing Competition from Roche's HPV Business

  5. Meridian Bio Q3 Revenues Increase 12 Percent

Sponsorships

Privacy Policy.  Copyright © 2016 Genomeweb LLC.  All Rights Reserved.